Prescription medicine
Magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients Brand names: Suflave
Magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients (Suflave) is a prescription medicine with an FDA approval on record since 2023. No generic is listed; pharmacies paid $61.65 per unit (Suflave powder) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients FDA label on DailyMed (effective January 31, 2026, Azurity Pharmaceuticals, Inc.); the NDA 215344 record on Drugs@FDA; every magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients label on DailyMed.
Highlights of the record
FDA label of January 31, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSUFLAVE is indicated for the cleansing of the colon as a preparation for colonoscopy in adults.
Forms and strengths
Kit.
On the market
- Earliest approval on file
- June 15, 2023 Suflave, Azurity; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- August 2, 2044 Suflave for solution; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $61.65 per unit Suflave powder
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 102 through July 30, 2026
What is magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients used for?
From the label: indications and usageSUFLAVE is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUFLAVE is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.
Source: FDA drug label (SUFLAVE), Azurity Pharmaceuticals, Inc., effective January 31, 2026 (SPL set d5710a04-2b0a-402c-a8b0-025766f1a437), via openFDA; the full label on DailyMed
What does the patient leaflet for magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about SUFLAVE?SUFLAVE and other bowel preparations can cause serious side effects, including: Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause: abnormal heartbeats that can cause death. seizures. This can happen even if you have never had a seizure. kidney problems. Your chance of having fluid loss and changes in body salts with SUFLAVE is higher if you: have heart problems. have kidney problems. take water pills (diuretics), high blood pressure medicine, or non-steroidal anti-inflammatory drugs (NSAIDs). Tell your healthcare provider right away if you have any of these symptoms of a loss of too much body fluid (dehydration) while taking SUFLAVE: vomiting • urinating less often than normal dizziness • headache See “What are the possible side effects of SUFLAVE?” for more information about side effects.
From the patient leaflet: How should I store SUFLAVE?Store SUFLAVE at room temperature between 68°F to 77°F (20°C to 25°C). Store mixed (reconstituted) SUFLAVE solution in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze. Used mixed (reconstituted) SUFLAVE solution within 24 hours. After 24 hours, throw away (discard) any mixed (reconstituted) SUFLAVE solution that is not used. Keep SUFLAVE and all medicines out of the reach of children.
Source: FDA drug label (SUFLAVE), Azurity Pharmaceuticals, Inc., effective January 31, 2026 (SPL set d5710a04-2b0a-402c-a8b0-025766f1a437), via openFDA; the full label on DailyMed
Is there a generic for magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients (Suflave)?
No generic magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 4 patents for Suflave for solution, the last expiring on August 2, 2044. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2023 earliest approval on file
- 2044 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients (Suflave)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $61.65 per unit (Suflave powder), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Suflave powder (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Suflave powder | Brand | $61.65 per unit | n/a | no change |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients label say about other medicines?
The magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients label names 5 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Bisacodyl | drug interactions | Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking SUFLAVE [see Warnings and Precautions ( 5.5 )]. |
| Chlorpromazine | drug interactions | Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium. |
| Digoxin | drug interactions | Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium. |
| Penicillamine | drug interactions | Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium. |
| Tetracycline | drug interactions | Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and penicillamine at least 2 hours before and not less than 6 hours after administration of each dose of SUFLAVE to avoid chelation with magnesium. |
Check magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients against other medicines
Source: FDA drug label (SUFLAVE), Azurity Pharmaceuticals, Inc., effective January 31, 2026 (SPL set d5710a04-2b0a-402c-a8b0-025766f1a437), via openFDA; the full label on DailyMed
What do FAERS reports show for magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients?
The FDA Adverse Event Reporting System holds 102 reports that list magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 3 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Magnesium sulfate, polyethylene glycol 3350 and 3 other ingredients side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other